ASTCT Pharmacy SIG Journal Club Session
Enduring online activity – Expires November 18, 2027
Original live activity – November 18, 2026

TARGET AUDIENCE
This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing hematopoietic stem cell transplantation and cellular therapy.

PROGRAM OVERVIEW
This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the November Journal Club session, Drs. Hosick and Robida will present two articles related to:

- CRISPR-Cas9 gene-edited allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in acute myeloid leukemia (AML)
- Azacitidine-venetoclax versus induction chemotherapy for the treatment of acute myeloid leukemia (AML)

LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:

- List the most common post-hematopoietic cell transplantation (HCT) maintenance strategies and limitations of these standards of care
- Discuss the efficacy and clinical implications of Tremtelectogene empogeditemcel (trem-cel) for maintenance in acute myeloid leukemia after allogenic HCT
- Recognize the risks and toxicities associated with CRISPR-edited gene products in general, and specifically trem-cel in post-HCT patients
- Review up-front treatment options for newly diagnosed, induction-eligible acute myeloid leukemia (AML) and the rationale for testing azacitidine–venetoclax against standard intensive 7+3 induction chemotherapy
- Describe the safety and efficacy of azacitidine–venetoclax versus intensive induction chemotherapy for event-free survival in the PARADIGM phase 2 trial
- Discuss clinical utility and applicability of azacitidine–venetoclax as up-front therapy for induction-eligible AML

FACULTY & ARTICLES
Madeleine Hosick, PharmD
PGY-2 Pharmacy Resident
Duke University Hospital
Article: CRISPR–Cas9 CD33-delet hematopoietic cell transp gemtuzumab ozogamicin AML: a phase 1/2 trial

Olivia Robida, PharmD
PGY-2 Pharmacy Resident
The Ohio State University - Wexner Medical Center
Article: Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia

Instructions for Participation and Requesting Credit
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the posttest and evaluation form. A score of at least 75% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.

Credit Fulfillment

- If you are a pharmacist requesting ACPE credits, your credit request will be uploaded to CPE Monitor within 60 days

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity, UAN JA0007204-9999-26-068-H01-P, qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. **Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.** Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all of their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data

collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosures
The individuals listed below disclosed the following relevant financial relationships:

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Ashley Smeaton, MHA	TFF Staff	No relevant financial disclosures	N/A	N/A
Brandi Anders, PharmD, BCOP, CPP	Reviewer/Mentor	No relevant financial disclosures	N/A	N/A
Emily Sajda, PharmD	Reviewer/Mentor	No relevant financial disclosures	N/A	N/A
Haedyn Smith	ASTCT Staff	No relevant financial disclosures	N/A	N/A
Harpreet Sandhu, PharmD, MS, BCOP	Reviewer/Mentor	No relevant financial disclosures	N/A	N/A
Gwen Hua, PharmD, BCOP	Reviewer/Mentor	No relevant financial disclosures	N/A	N/A
Madeleine Hosick, PharmD	Faculty	No relevant financial disclosures	N/A	N/A
Melanie Rudisill, PharmD, BCOP	Reviewer/Mentor	1. Novartis	1. Advisory Board	This relationship was mitigated by ending in September 2025. All final review decisions concerning content, learning objectives, and evaluation questions were made by a non-conflicted Planning Committee Member.
Olivia Robida, PharmD	Faculty	No relevant financial disclosures	N/A	N/A

Pearl Abraham, PharmD, BCPS, BCOP	Reviewer/Mentor	1. Azurity, Sanofi	1. Non-CE Consulting	The following relationship was mitigated by ending: • Azurity in January 2026 All final review decisions concerning content, learning objectives, and evaluation questions were made by a non-conflicted Planning Committee Member.

DISCLOSURE OF UNLABELED USE

TFF and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and ASTCT assume no liability for the information herein.

CONTACT INFORMATION

If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.